Publication:
Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.

No Thumbnail Available

Date

2018-08-16

Authors

Hruskova, Zdenka
Pippias, Maria
Stel, Vianda S
Abad-Díez, Jose M
Benítez Sánchez, Manuel
Caskey, Fergus J
Collart, Frederic
De Meester, Johan
Finne, Patrik
Heaf, James G

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Data for outcomes of patients with end-stage renal disease (ESRD) secondary to systemic sclerosis (scleroderma) requiring renal replacement therapy (RRT) are limited. We examined the incidence and prevalence of ESRD due to scleroderma in Europe and the outcomes among these patients following initiation of RRT. Registry study of incidence and prevalence and a matched cohort study of clinical outcomes. Patients represented in any of 19 renal registries that provided data to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry between 2002 and 2013. Scleroderma as the identified cause of ESRD. Incidence and prevalence of ESRD from scleroderma. Recovery from RRT dependence, patient survival after ESRD, and graft survival after kidney transplantation. Incidence and prevalence were calculated using population data from the European Union and standardized to population characteristics in 2005. Patient and graft survival were compared with 2 age- and sex-matched control groups without scleroderma: (1) diabetes mellitus as the cause of ESRD and (2) conditions other than diabetes mellitus as the cause of ESRD. Survival analyses were performed using Kaplan-Meier analysis and Cox regression. 342 patients with scleroderma (0.14% of all incident RRT patients) were included. Between 2002 and 2013, the range of adjusted annual incidence and prevalence rates of RRT for ESRD due to scleroderma were 0.11 to 0.26 and 0.73 to 0.95 per million population, respectively. Recovery of independent kidney function was greatest in the scleroderma group (7.6% vs 0.7% in diabetes mellitus and 2.0% in other primary kidney diseases control group patients, both P No data for extrarenal manifestations, treatment, or recurrence. Survival of patients with scleroderma who receive dialysis for more than 90 days was worse than for those with other causes of ESRD. Patient survival after transplantation was similar to that observed among patients with ESRD due to other conditions. Patients with scleroderma had a higher rate of recovery from RRT dependence than controls.

Description

MeSH Terms

Adult
Aged
Case-Control Studies
Cause of Death
Europe
Female
Humans
Internationality
Kaplan-Meier Estimate
Kidney Failure, Chronic
Male
Middle Aged
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Registries
Renal Replacement Therapy
Retrospective Studies
Risk Assessment
Scleroderma, Systemic
Survival Analysis
Treatment Outcome
Young Adult

DeCS Terms

CIE Terms

Keywords

Systemic sclerosis, dialysis, disease course, disease registry, end-stage renal disease (ESRD), incidence, kidney transplantation, mortality, outcomes, prognosis, renal recovery, renal replacement therapy (RRT), scleroderma

Citation